Recently, Elios Biotechnology (Shanghai) Co., Ltd. (referred to as: Elios) announced the completion of nearly 100 million yuan in Series A financing. This round of financing was jointly led by Matrix Partners and Legend Capital, and followed by investors such as Shanghai Yishui Liushan. This round of financing will be used for the construction of the R&D center of Airios membrane materials, the construction and scale improvement of the production base of filter products for pharmaceutical processes, and the expansion of the professional talent team.
Founded in 2021, Elios focuses on the development and application of technical products for pharmaceutical process technology, and is committed to providing pharmaceutical companies with high-quality separation and purification solutions that meet domestic and foreign regulatory requirements.
media coverage
Yiou Investment Community Investment Network
Related events
- Elios Biotech completes Series A financing2022-10-14
- Innovative drug CDMO one-stop service platform Shanghai Yaotan completed nearly 200 million yuan in Series A financing2022-03-29
- Shipwang Pharmaceutical completed a round of financing of over 400 million yuan, led by Zhengxingu 2022-03-23
- Weiweijun, a micro-ecological AI pharmaceutical company, completed nearly $100 million in Series B financing2021-12-22
- Chip IP company Xinyaohui completed A round of financing of over 500 million yuan, led by Gao Rong2021-05-19
This article is reproduced from: https://readhub.cn/topic/8k6fLDC0Gnd
This site is for inclusion only, and the copyright belongs to the original author.